Owens & Minor, Inc. Completes Sale of Products & Healthcare Services Business to Platinum Equity
MWN-AI** Summary
Owens & Minor, Inc. (NYSE: OMI) has completed the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to Platinum Equity for $375 million in cash. This transaction allows the company to undergo a strategic transformation, rebranding itself as Accendra Health, Inc., a focused leader in the home-based care market. Edward A. Pesicka, President & CEO, highlighted the significance of this sale, stating that it positions Accendra Health to better serve patients with chronic conditions by concentrating on their home-based care needs.
With the P&HS segment divested, Accendra Health is set to sharpen its focus on its Apria and Byram brands, ensuring that capital deployment, corporate strategy, and operations are aligned to foster sustainable growth and long-term value. The completion of this sale not only enhances the company’s resilience but also retains a 5% equity stake, preserving tax attributes valued at over $150 million.
The shift comes as Owens & Minor aims to adapt to evolving healthcare demands, particularly in the context of home-based care, which is becoming increasingly critical in the industry. The sale signifies a pivotal moment for Accendra Health as it navigates its future in a transforming healthcare landscape.
Investors are cautioned regarding forward-looking statements related to the company's future performance, including financial expectations and operational strategies post-sale. Risks and uncertainties could potentially affect actual results, and stakeholders are encouraged to consult the company's SEC filings for a comprehensive view of risk factors and further information.
The move marks a strategic evolution for Owens & Minor, now positioned to capitalize on its healthcare capabilities under the new branding of Accendra Health.
MWN-AI** Analysis
In light of Owens & Minor, Inc.'s recent strategic pivot following the completion of its sale of the Products & Healthcare Services (P&HS) segment to Platinum Equity, investors should closely reassess the company's positioning as it transforms into Accendra Health, a focused leader in the burgeoning home-based care market. The $375 million cash transaction, coupled with a retained equity stake and preserved tax attributes, positions Accendra Health to leverage its enhanced operational focus and brand optimization.
This sale marks a crucial inflection point, allowing Accendra to allocate its resources effectively towards its Apria and Byram brands, ultimately enhancing its competitive standing. The management's goal is to dedicate capital deployment and operational execution towards sustaining durable growth, which is pertinent in an increasingly competitive healthcare landscape.
Investors should note that the home health care segment is projected to grow significantly, driven by an aging population and increased emphasis on chronic disease management. With a widening array of services catered towards patients requiring home-based care, Accendra’s strategic focus aligns with market trends. Stakeholders should cautiously evaluate the company's financial trajectory post-split and consider the potential volatility inherent in transition phases.
The company’s future results will largely depend on how effectively it integrates its offerings while navigating the current healthcare environment. The focus on operational execution and sustained innovation will be key determinants of success.
However, prospective investors must remain vigilant about forward-looking statements, understanding inherent risks and uncertainties as outlined in prior disclosures. Maintaining a diversified portfolio may mitigate risks associated with potential unforeseen challenges during this transitional phase. Monitoring Accendra's capital allocation and growth strategies will be essential for making informed investment decisions. Overall, while promising, these developments necessitate a balanced and cautious approach from investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
The Transaction Includes the Owens & Minor Brand, and the Remaining Company Will Become Accendra Health
Completes the Company’s Transformation into a Pure Play Leader in the Home-Based Care Market
Owens & Minor, Inc. (NYSE: OMI) (the “Company”) announced the completion of the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to Platinum Equity and is renaming the publicly traded parent company Accendra Health, Inc.
“Today’s announcement marks an inflection point in the strategic transformation of Owens & Minor into Accendra Health, a leading nationwide pure play home based care platform. The completion of the sale of the P&HS segment enables the Company to become a more focused and resilient organization that is well equipped to deliver on our commitment to supporting patients with chronic conditions by providing what they need for home-based care. We’re energized by what lies ahead and are confident that our comprehensive product portfolio, expansive payor contracts, and national footprint position us advantageously for the future evolution of home-based care,” said Edward A. Pesicka, President & Chief Executive Officer.
“With Accendra’s full attention dedicated to our Apria and Byram brands, our capital deployment, corporate strategy, and operational execution are focused and aligned to support durable growth and create long-term value,” Pesicka concluded.
On October 7, Owens & Minor, Inc. announced a definitive agreement to sell its P&HS segment along with the Owens & Minor brand. The Company completed the sale to Platinum Equity for $375 million in cash, subject to certain customary adjustments for cash, indebtedness, net working capital, and transaction expenses, and a 5% retained equity stake while also preserving tax attributes in excess of $150 million.
Safe Harbor
This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This release contains certain “forward looking” statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this release regarding our future prospects and performance, including our expectations with respect to our financial performance, our 2025 financial results, our expectations regarding the performance of our business following the completion of the sale of the P&HS business, our cost saving initiatives, future indebtedness and growth, industry trends, as well as statements related to our expectations regarding the performance of our business, including our ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to Owens & Minor’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 28, 2025, including the section captioned “Item 1A. Risk Factors,” as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from its current estimates. These filings are available at www.owens-minor.com . Given these risks and uncertainties, Owens & Minor can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. Owens & Minor specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
OMI-IR
View source version on businesswire.com: https://www.businesswire.com/news/home/20251231395792/en/
Investors
Will Parrish
Vice President | Strategy, Corporate Development, & Investor Relations
Investor.Relations@owens-minor.com
Media
Darla Turner
Media@owens-minor.com
FAQ**
How does the sale of Owens & Minor Inc. OMI's P&HS segment to Platinum Equity impact the company's positioning in the home-based care market?
What are the main strategic priorities for Accendra Health following the transformation from Owens & Minor Inc. OMI, particularly regarding the Apria and Byram brands?
Can you elaborate on how Owens & Minor Inc. OMI’s retained equity stake and preserved tax attributes will influence future financial performance?
What are some anticipated challenges Owens & Minor Inc. OMI may face in achieving its growth objectives as Accendra Health in the evolving healthcare landscape?
**MWN-AI FAQ is based on asking OpenAI questions about Owens & Minor Inc. (NYSE: OMI).
NASDAQ: OMI
OMI Trading
-38.86% G/L:
$2.80 Last:
1,268,314 Volume:
$2.74 Open:
